Sanofi Asks 340B Hospitals for Information on Purchases of Its Top-Selling Drug

Sanofi is reportedly asking hospitals for data relating to 340B purchases of Dupixent.
French drugmaker Sanofi has reportedly asked some hospitals for data relating to 340B purchases of a popular drug used to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Drug Industry-funded Think Tank Raises Questions About 340B Hospitals’ Charity Care

The Pioneer Institute for Public Policy Research compared 29 financially strong 340B hospitals/health systems’ performance on charity care in an Aug. 19 brief.
More transparency surrounding 340B hospital operations is needed to ensure drug discount savings are being used to improve patient care, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Federal Court Grants Texas Hospitals’ Request to Temporarily Block DSH Calculation Changes

A federal court sided with a group of Texas hospitals’ efforts to block an HHS rule.
A federal court last week sided with a group of Texas hospitals’ efforts to block—at least temporarily—a Department of Health [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AHA Raises ‘Serious Concerns’ with MedPAC’s Direction on 340B

American Hospital Association logo
AHA officials penned a Medical Economics op-ed on “the truth behind growth of the 340B prescription drug program.”
A major hospital advocacy group recently urged congressional advisers to “carefully consider” the potential negative consequences of any new efforts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

GSK Announces Refunds for 340B Overcharges

GlaxoSmithKline will refund covered entities that purchased certain formulations of a severe asthma treatment in 2022.
GlaxoSmithKline (GSK) will refund covered entities that purchased certain formulations of a severe asthma treatment medication in the third quarter [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B ESP Updates Claims Submission Policy, Stakeholders Voice Concerns About Compliance

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.
340B covered entities could soon be required to share new information—including reimbursement amounts, ship to dates and ship to locations—as [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Defends Subpoenas; Updates in Missouri, Mississippi, Maryland

Lawsuits challenging 340B contract pharmacy access laws recently heated up in Missouri, Mississippi and Maryland.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Former Pfizer Exec. Slams 340B, Says IRA Will Worsen Program in New Op-Ed 

Kirsten Axelsen, a consultant and former Pfizer executive, cautioned that the 340B program “will be even worse” under the IRA in an Aug. 13 op-ed.
A former Pfizer executive and current biopharmaceutical consultant took aim this week at what she called the “poorly managed” 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

UPDATED: AbbVie Ends Voluntary 340B Discount Pricing for Dozens of Orphan Drugs

AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to covered entities subject to such exclusions.
AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to rural referral centers (RRC), sole [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Massachusetts’ 340B Contract Pharmacy Access Bill Fails to Move in Formal Session, Stakeholders Remain Hopeful

A contract pharmacy access bill could still pass in Massachusetts despite the end of the formal legislative session.
Although Massachusetts lawmakers left Beacon Hill this month without passing a long-stalled 340B contract pharmacy access bill, provider groups say [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live